Changeflow GovPing Pharma & Drug Safety CRISPR/Cas13a Kit for Rapid ALV-J Detection
Routine Notice Added Final

CRISPR/Cas13a Kit for Rapid ALV-J Detection

Favicon for changeflow.com ChangeBridge: Patent Apps - Biotech (C12N)
Published March 26th, 2026
Detected March 27th, 2026
Email

Summary

The USPTO has published a patent application for a CRISPR/Cas13a kit designed for the rapid detection of avian leukosis virus subgroup J (ALV-J). This application details a method combining CRISPR/Cas13a with recombinase aided amplification for improved sensitivity and specificity in detecting ALV-J.

What changed

This document is a patent application (US20260085369A1) filed with the USPTO for a kit and method to rapidly detect avian leukosis virus subgroup J (ALV-J) using a CRISPR/Cas13a system. The described method combines CRISPR/Cas13a with recombinase aided amplification (RAA) to enhance detection sensitivity and specificity, differentiating ALV-J from other avian viruses. The application highlights the method's efficiency, low equipment requirements, and suitability for on-site detection.

This patent application does not impose immediate regulatory obligations on entities. However, it signifies potential future developments in diagnostic tools for avian diseases. Companies involved in veterinary diagnostics, biotechnology, or animal health may find this technology relevant for research and development, potentially leading to new commercial products or diagnostic services in the future.

Source document (simplified)

← USPTO Patent Applications

KIT FOR RAPID DETECTION OF AVIAN LEUKOSIS VIRUS SUBGROUP J BASED ON CRISPR/Cas13a SYSTEM

Application US20260085369A1 Kind: A1 Mar 26, 2026

Inventors

Xi LAN, Qigui WANG, Haiwei WANG, Shutao CHEN, Min TAN, Zhifu CUI, Yongju ZHAO

Abstract

Provided is a kit for rapid detection of avian leukosis virus subgroup J (ALV-J) based on a CRISPR/Cas13a system. The method is based on the combination of the CRISPR/Cas13a system and recombinase aided amplification (RAA) for ALV-J detection. An oligonucleotide probe is designed as a substrate for CRISPR/Cas13a trans-cleavage and produces a detectable signal. The method can substantially improve detection sensitivity by amplifying a detection signal twice by RAA and T7 transcription. The detection method further exhibits excellent specificity, allowing for clear differentiate from other avian viruses. It does not require expensive experimental equipment and special laboratory environment, and it is rapid and efficient. The method is of great significance for biological research and on-site detection of ALV-J.

CPC Classifications

C12Q 1/702 C12N 9/22 C12N 15/11 C12N 2310/20 C12N 2320/10 C12Q 2600/158

Filing Date

2025-03-14

Application No.

19080176

View original document →

Classification

Agency
USPTO
Published
March 26th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085369A1

Who this affects

Applies to
Drug manufacturers Food manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Diagnostic Testing Biological Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Food Safety Public Health

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.